We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Miss
Anna
Haire
+44 (0)7464492509
Anna.haire@kcl.ac.uk
Dr
Richard
Bryan
+44 1214147870
r.t.bryan@bham.ac.uk
Bladder cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Seeing blood in the urine (visible haematuria), or having blood detected in a urine sample by your GP (non-visible haematuria), is common. However, haematuria is also a symptom that is associated with bladder cancer and so needs to be investigated further by referral to hospital. About 10% of patients referred to haematuria clinic will be diagnosed with bladder cancer – but for most patients, no reason is identified, or patients are diagnosed with benign conditions such as urine infections or kidney stones.
As part of the investigations that take place in hospital, patients undergo flexible cystoscopy (flexi)- a narrow flexible camera is passed through the water pipe into the bladder to see any abnormalities that might be in the bladder. However, flexi is an invasive procedure which can be uncomfortable and is not perfect - a flexi inspection of the bladder will miss bladder cancer in around 1 in 7 to 1 in 10 patients. When we look at results from the UK and worldwide for all patients referred to haematuria clinics, we see that over 80% of patients do not have any abnormalities diagnosed. Therefore, many patients undergo flexi when they may not need to. However, at present, it is impossible to know who these patients are before the investigations are carried out.
Researchers have been working to identify new ways to diagnose bladder cancer instead of flexi. Urine tests are showing the most promise for this as when a patient has bladder cancer, some of the cancer cells are shed from the lining of the bladder into the urine and the abnormalities in these cells can be detected.
Study aims:
With funding from Cancer Research UK, researchers at the University of Birmingham have developed a urine test which may be as good as flexi. In this study, we would like to find out how accurate this new urine test is. If we can show that the test is as good as (or even better than) flexi when used in haematuria clinic, then it could be used in the future to identify which patients may have bladder cancer and need to have a flexi, and which patients are very unlikely to have bladder cancer and do not need a flexi.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Previous diagnosis of bladder or upper tract urothelial cancer (UTUC) within the last 5 years2. Previous entry into the study3. Limited understanding of English (due to the lack of resource available to have translators in HCs to facilitate informed consent or provide the at-home urine sample collection kits with translated instructions)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Miss
Anna
Haire
+44 (0)7464492509
Anna.haire@kcl.ac.uk
Dr
Richard
Bryan
+44 1214147870
r.t.bryan@bham.ac.uk
The study is sponsored by University of Birmingham and funded by Cancer Research UK.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 57525
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
